Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Clinical Trial for Development of Guidelines of Adequate Blood Pressure Lowering in the Subacute Ischemic Stroke Patients Due to Intracranial Atherosclerosis
Brief Summary: To develop adequate blood pressure (BP) lowering strategy after subacute ischemic stroke patients with symptomatic severe intracranial atherosclerosis.

Primary hypothesis of this study is that aggressive BP control (lowering systolic BP between 110mmHg and 120mmHg) will not increase the ischemic lesion volumes in hemisphere compared to modest BP lowering (lowering systolic BP between 130mmHg and 140mmHg) in the patients with symptomatic severe intracranial atherosclerosis.


Options:
A: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
B: Arm Label: Intensive Strategy; Type: OTHER; Interventions: Drug: Triatec 10 mg, Drug: Triatec HCT 5, Drug: Lasix 25, Drug: Micardis 80 mg, Drug: Micardis plus 80/12.5, Drug: Catapresan TTS 2, Drug: Norvasc 10 mg, Drug: Triatec 5 mg, Drug: Pluscor | Arm Label: Usual Strategy; Type: OTHER; Interventions: Drug: Triatec 10 mg, Drug: Triatec HCT 5, Drug: Lasix 25, Drug: Micardis 80 mg, Drug: Micardis plus 80/12.5, Drug: Catapresan TTS 2, Drug: Norvasc 10 mg, Drug: Triatec 5 mg, Drug: Pluscor | Intervention Type: DRUG; Name: Triatec 10 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Triatec HCT 5; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Lasix 25; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Micardis 80 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Micardis plus 80/12.5; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Catapresan TTS 2; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Norvasc 10 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Triatec 5 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Pluscor; Assigned to Arm(s): Intensive Strategy, Usual Strategy
C: Arm Label: Aggressive BP lowering; Type: EXPERIMENTAL; Interventions: Procedure: Aggressive BP lowering | Arm Label: Modest BP lowering; Type: ACTIVE_COMPARATOR; Interventions: Procedure: modest blood pressure lowering | Intervention Type: PROCEDURE; Name: Aggressive BP lowering; Assigned to Arm(s): Aggressive BP lowering | Intervention Type: PROCEDURE; Name: modest blood pressure lowering; Assigned to Arm(s): Modest BP lowering
D: Arm Label: Blood pressure; Type: EXPERIMENTAL; Interventions: Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone | Intervention Type: DRUG; Name: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone; Assigned to Arm(s): Blood pressure

Answer: C